Publicaciones en colaboración con investigadores/as de Hospital del Mar (22)

2024

  1. Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer

    Breast, Vol. 76

  2. Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial

    ESMO Open, Vol. 9, Núm. 9

2023

  1. Evaluation of triple negative breast cancer with heterogeneous immune infiltration

    Frontiers in Immunology, Vol. 14

  2. Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 1, pp. 67-80

  3. Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial

    The oncologist, Vol. 28, Núm. 1, pp. 23-32

  4. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

    Neuro-Oncology, Vol. 25, Núm. 1, pp. 157-166

2022

  1. Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer

    Cancer research, Vol. 82, Núm. 24, pp. 4670-4679

2021

  1. Epstein–Barr Virus+ B Cells in Breast Cancer Immune Response: A Case Report

    Frontiers in Immunology, Vol. 12

  2. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2 -Negative Advanced Breast Cancer: A Randomized Clinical Trial

    JAMA Oncology, Vol. 7, Núm. 12, pp. 1791-1799

  3. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients

    Cancer Treatment Reviews, Vol. 83

2019

  1. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study

    Clinical Breast Cancer, Vol. 19, Núm. 2, pp. 105-112

2018

  1. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer

    Nature Cell Biology, Vol. 20, Núm. 2, pp. 211-221

  2. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial

    The Lancet Oncology, Vol. 19, Núm. 6, pp. 812-824

  3. Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

    Melanoma Research, Vol. 28, Núm. 3, pp. 195-203

  4. Erratum to: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer (Nature Cell Biology, (2018), 20, 2, (211-221), 10.1038/s41556-017-0021-z)

    Nature Cell Biology

  5. P95HER2–T cell bispecific antibody for breast cancer treatment

    Science Translational Medicine, Vol. 10, Núm. 461

  6. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

    Investigational New Drugs, Vol. 36, Núm. 5, pp. 848-859

2017

  1. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer

    Cancer Research, Vol. 77, Núm. 9, pp. 2213-2221

2016

  1. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428